Trial Profile

An Open Label Study With OHR/AVR118 in Advanced Cancer Patients with Anorexia-Cachexia.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVR 118 (Primary)
Indications Anorexia; Cachexia
Focus Therapeutic Use

Most Recent Events

26 Mar 2013 Results have been reported in an Ohr Pharmaceutical media release.
21 Mar 2013 Primary endpoint 'Bodyweight' (weight gain) has not been met according to an Ohr Pharmaceutical media release.
26 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com